Nottingham-based CDMO/CRO is poised to further growth in the UK and the US with new investor
Quotient Sciences and investment firm Permira have announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in the Nottingham-based CDMO from companies controlled by GHO Capital and other investors for an undisclosed sum.
Chief Executive Officer Mark Egerton and the management team will continue to lead Quotient.
“We are delighted to partner with Permira to drive Quotient through our continued evolution,” said CEO Mark Egerton. “The investment by the Permira Funds will support Quotient’s continued growth plans, which include broadening our core services portfolio and expanding our formulation development and manufacturing capabilities to meet the demands of our growing customer base.”
Headquartered in Nottingham, UK, Quotient Sciences has brought innovation to the pharmaceutical services sector through its unique Translational Pharmaceutics platform, which is proven to accelerate development timelines, reduce development costs, and drive improvement in R&D productivity.
The business employs more than 850 people across six operating sites in the U. and the US and has experienced substantial growth over recent years. Quotient has seen annual revenues in excess of £100 million.
Quotient Sciences and its disruptive approach to pharmaceutical drug development have created a truly unique business model
“Quotient Sciences and its disruptive approach to pharmaceutical drug development have created a truly unique business model," said Marcel Lacaze, Principal in the Global Healthcare Group of Permira based in London.
Lacaze added: "With GHO’s support, the business has developed strongly in recent years and we look forward to partnering with Mark and his team in continuing to grow this exciting company.”
The Partners at GHO Capital have enjoyed working with the Quotient team since 2015. During this period, the business has achieved a global footprint, replicated its Translational Pharmaceutics in the US, and validated itself as a commercial drug product manufacturer.
"Having more than doubled its capacity and made large investments in operational infrastructure, Quotient is well placed to continue its strong performance, and we look forward to seeing their continued success in partnership with Permira," Lacaze concluded.